This site uses cookies. You can read how we use them in our privacy policy.

pulmonary fibrosis

and infection

sign up to receive our news and updates

  • This form collects your name and email address so that we can keep you updated with news and information about Breathing Matters. Please check our Privacy Policy to see how we protect and manage your data.

Stories from June, 2020


  • Related articles
  • Categories
  • Archives

Breathing Matters – Partner of the 2020 Respiratory Health Campaign

Breathing Matters is honoured to work with Health Awareness on the 2020 Respiratory Health campaign.

The campaign features exclusive content from key thought leaders and industry voices about respiratory conditions and external risk factors such as air pollution and COVID-19.

There are a wealth of great articles, including:

  • One person dies every hour of pulmonary fibrosis
  • Improve your quality of life with cleaner indoor air
  • Can your income make your asthma worse?
  • Breathlessness – when to seek help
  • Improving air quality around schools to protect children

A printed publication is enclosed within every copy of the Guardian newspaper and the content is available online at

Definitely worth a read!





Stark Facts about Pulmonary Fibrosis

  • Without treatment, 50% of Pulmonary Fibrosis [PF] patients will die within 3 years of diagnosis. Treatment extends life expectancy to 7-8 years.
  • Men are nearly twice as likely as women to suffer from PF.
  • There are 6000 new cases of PF every year in the UK.
  • 70,000 people are living with PF in the UK.
  • More than 30,000 people will be diagnosed with PF in the 27 EU countries each year.
  • PF is more common than all leukaemias combined.
  • 3-20% of people with PF have another family member with PF.
  • Most patients can be diagnosed from 1 to 12 years after their first symptoms.
  • Pulmonary fibrosis costs the NHS £88 million per year.
  • 5 million people worldwide have PF.
  • 1 in 3 PF patients are expected to die within the next 12 months.
  • One person dies every hour of PF.
  • One in every 100 people who die in the UK are from PF.
  • There are 5,000 PF deaths per year.
  • 9,000 admissions and 86,000 hospital bed days accounted for by IPF patients per year.





New COVID-19 Clinical Trials Funded

Professor Joanna Porter was delighted to be awarded over £2M from LifeArc to run two clinical trials in COVID-19.

The first, ATTRACT, is in collaboration with Vicore Pharma, whom we have worked with for over 10 years on developing novel approaches for pulmonary fibrosis. The drug, VP01 (Compound 21; C21) is hoped to recalibrate the renin-angiotensin- system towards repair rather than inflammation.  This should indirectly help our research into pulmonary fibrosis too.

The second study, COVASE, is a collaboration with Veni Papayannopoulos and Veronique Brilaut at The Francis Crick Institute, to investigate an approved nebulised recombinant human deoxyribonuclease I (Dornase alfa) to reduce hyperinflammation from neutrophil extracellular traps in the lungs of hospitalised participants with COVID-19.

ATTRACT is open to recruitment and COVASE will open in the next two weeks.

Here’s the LifeArc press release with more info: